Ansa Biotechnologies
Emeryville, California, United States · Biotechnology · 73 employees
Ansa Biotechnologies is redefining DNA synthesis with a bold commitment to quality, customer satisfaction, and success. The Ansa On-Time Guarantee is simple and straightforward: your complete order on time or it’s free. This unprecedented level of service reliability and predictability is made possible by Ansa’s dedicated team of experts and proprietary enzymatic synthesis platform, which can rapi
Funding history
- Venture - Series Unknown — $46.4M — Dec 2025
- Venture - Series Unknown — $45.2M — Oct 2025
- Series B — $54.4M — Oct 2025
- Venture - Series Unknown — $5.0M — Oct 2021
- Seed — $46.4M — Jul 2020
Recent signals
- Mar 31, 2026: Ansa Biotechnologies Appoints Matthias Arenskötter as Chief Operating Officer
- Dec 10, 2025: Raised $46.4M in Venture - Series Unknown
- Dec 09, 2025: Ansa Biotechnologies Appoints Geoff Hamilton as Chief Financial Officer and Chief Business Officer
- Oct 02, 2025: Raised $45.2M in Venture - Series Unknown
- Oct 01, 2025: Raised $54.4M in Series B
- Feb 22, 2024: Ansa Biotechnologies Appoints Jason T. Gammack as CEO and Prepares for Launch of Rapid Enzymatic Synthesis Service for Complex DNA Sequences
- Oct 15, 2021: Raised $5.0M in Venture - Series Unknown
- Jul 09, 2020: Raised $46.4M in Seed
See plans & pricing → Track Ansa Biotechnologies’s funding, hiring, and signals — with verified contacts — on Fundz.